These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 33484777)

  • 1. Minimally Invasive Nasal Depot (MIND) technique for direct BDNF AntagoNAT delivery to the brain.
    Padmakumar S; Jones G; Pawar G; Khorkova O; Hsiao J; Kim J; Amiji MM; Bleier BS
    J Control Release; 2021 Mar; 331():176-186. PubMed ID: 33484777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osmotic core-shell polymeric implant for sustained BDNF AntagoNAT delivery in CNS using minimally invasive nasal depot (MIND) approach.
    Padmakumar S; Jones G; Khorkova O; Hsiao J; Kim J; Bleier BS; Amiji MM
    Biomaterials; 2021 Sep; 276():120989. PubMed ID: 34252799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimally invasive nasal infusion (MINI) approach for CNS delivery of protein therapeutics: A case study with ovalbumin.
    Di Francesco V; Chua AJ; Davoudi E; Kim J; Bleier BS; Amiji MM
    J Control Release; 2024 Aug; 372():674-681. PubMed ID: 38909700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct CNS delivery of proteins using thermosensitive liposome-in-gel carrier by heterotopic mucosal engrafting.
    Pawar GN; Parayath NN; Nocera AL; Bleier BS; Amiji MM
    PLoS One; 2018; 13(12):e0208122. PubMed ID: 30517163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The blood-brain barrier and nasal drug delivery to the central nervous system.
    Miyake MM; Bleier BS
    Am J Rhinol Allergy; 2015; 29(2):124-7. PubMed ID: 25785753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal Drug Delivery: A Non-Invasive Approach for the Better Delivery of Neurotherapeutics.
    Kumar H; Mishra G; Sharma AK; Gothwal A; Kesharwani P; Gupta U
    Pharm Nanotechnol; 2017; 5(3):203-214. PubMed ID: 28521670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endonasal CNS Delivery System for Blood-Brain Barrier Impermeant Therapeutic Oligonucleotides Using Heterotopic Mucosal Engrafting.
    Pawar G; Parayath NN; Sharma AA; Coito C; Khorkova O; Hsiao J; Curry WT; Amiji MM; Bleier BS
    Front Pharmacol; 2021; 12():660841. PubMed ID: 33953687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Formulation considerations for improving intranasal delivery of CNS acting therapeutics.
    Patel D; Thakkar H
    Ther Deliv; 2022 Jul; 13(7):371-381. PubMed ID: 36416617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood-brain barrier: an excellent platform for brain targeting.
    Pardeshi CV; Belgamwar VS
    Expert Opin Drug Deliv; 2013 Jul; 10(7):957-72. PubMed ID: 23586809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insights into direct nose to brain delivery: current status and future perspective.
    Mittal D; Ali A; Md S; Baboota S; Sahni JK; Ali J
    Drug Deliv; 2014 Mar; 21(2):75-86. PubMed ID: 24102636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CNS drug delivery systems: novel approaches.
    Pathan SA; Iqbal Z; Zaidi SM; Talegaonkar S; Vohra D; Jain GK; Azeem A; Jain N; Lalani JR; Khar RK; Ahmad FJ
    Recent Pat Drug Deliv Formul; 2009 Jan; 3(1):71-89. PubMed ID: 19149731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Traditional neurotherapeutics approach intended for direct nose to brain delivery.
    Abolhasanzadeh Z; Ashrafi H; Badr P; Azadi A
    J Ethnopharmacol; 2017 Sep; 209():116-123. PubMed ID: 28733193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS.
    Alcalá-Barraza SR; Lee MS; Hanson LR; McDonald AA; Frey WH; McLoon LK
    J Drug Target; 2010 Apr; 18(3):179-90. PubMed ID: 19807216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mathematical Modeling and Simulation to Investigate the CNS Transport Characteristics of Nanoemulsion-Based Drug Delivery Following Intranasal Administration.
    Kadakia E; Bottino D; Amiji M
    Pharm Res; 2019 Mar; 36(5):75. PubMed ID: 30923914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Development of Noninvasive Drug Delivery Systems to the Brain for the Treatment of Brain/Central Nervous System Diseases].
    Kanazawa T
    Yakugaku Zasshi; 2018; 138(4):443-450. PubMed ID: 29607986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Pharmacokinetics of Drugs Delivered to the Upper Nasal Space.
    Shrewsbury SB
    Pharmaceut Med; 2023 Nov; 37(6):451-461. PubMed ID: 37537422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intranasal Delivery of Nanoformulations: A Potential Way of Treatment for Neurological Disorders.
    Islam SU; Shehzad A; Ahmed MB; Lee YS
    Molecules; 2020 Apr; 25(8):. PubMed ID: 32326318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced analgesic responses after preferential delivery of morphine and fentanyl to the olfactory epithelium in rats.
    Hoekman JD; Ho RJ
    Anesth Analg; 2011 Sep; 113(3):641-51. PubMed ID: 21709146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal delivery to the central nervous system: mechanisms and experimental considerations.
    Dhuria SV; Hanson LR; Frey WH
    J Pharm Sci; 2010 Apr; 99(4):1654-73. PubMed ID: 19877171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The nasal approach to delivering treatment for brain diseases: an anatomic, physiologic, and delivery technology overview.
    Djupesland PG; Messina JC; Mahmoud RA
    Ther Deliv; 2014 Jun; 5(6):709-33. PubMed ID: 25090283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.